For the quarter ended June 2026, Regeneron (REGN) reported revenue of $4.29 billion, up 16.7% over the same period last year. EPS came in at $14.29, compared to $12.89 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.84 billion, representing a surprise of +11.74%. The company delivered an EPS surprise of +42.9%, with the consensus EPS estimate being $10.00.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Eylea (Aflibercept)(EYLEA HD and EYLEA)- US: $1.01 billion compared to the $935.89 million average estimate based on four analysts. The reported number represents a change of -12.1% year over year.
  • Revenues- EYLEA HD- United States: $596.3 million compared to the $548.4 million average estimate based on four analysts. The reported number represents a change of +51.7% year over year.
  • Revenues- EYLEA- United States: $412.2 million versus $387.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -45.4% change.
  • Revenues- Kevzara (sarilumab)- ROW: $62.5 million versus $63.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
  • Revenues- Collaboration: $2.46 billion compared to the $2.13 billion average estimate based on five analysts. The reported number represents a change of +31.9% year over year.
  • Revenues- Other Revenue: $193.3 million versus $232.99 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
  • Revenues- Net product sales: $1.64 billion versus the five-analyst average estimate of $1.49 billion. The reported number represents a year-over-year change of +0.7%.
  • Revenues- Total Sanofi collaboration revenue: $2.17 billion versus the four-analyst average estimate of $1.76 billion. The reported number represents a year-over-year change of +50.6%.
  • Revenues- Total Bayer collaboration revenue: $276 million compared to the $310.83 million average estimate based on four analysts. The reported number represents a change of -33.5% year over year.
  • Revenues- Praluent (alirocumab)- Total: $265.6 million versus the three-analyst average estimate of $230.44 million. The reported number represents a year-over-year change of +19.6%.
  • Revenues- Libtayo- Total: $489.4 million versus the three-analyst average estimate of $451.13 million. The reported number represents a year-over-year change of +30%.
  • Revenues- Kevzara (sarilumab)- Total: $205.9 million versus the three-analyst average estimate of $162.22 million. The reported number represents a year-over-year change of +35.3%.

View all Key Company Metrics for Regeneron here>>>

Shares of Regeneron have returned +11.3% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research